Education Canberra Uni medical development headed to market thanks to international investment

Canberra Uni medical development headed to market thanks to international investment

U.S. chemical company Strem Chemical Inc. has signed the University of Canberra’s first intellectual property licence to develop a synthetic catalyst useful in pharmaceutical processing.

Discovered by Associate Professor Ashraf Ghanem, a biomedical scientist at the University of Canberra, the catalyst helps to increase the efficiency of the drug manufacturing process, particularly for the drug Ritalin, which is used in the treatment of Attention Deficit Disorder and Attention Deficit Hyperactive Disorder.

The new catalyst produces a chemical reaction, allowing for the extraction of certain molecules at a high level of purity. Not only does this reduce the need for further processing, but lessens the risk of unintended side effects from use of the drug, meaning the drugs themselves will be both safer and cheaper, which could help reduce the cost to the consumer.

Deals such as this show the vital and important work being done by Australian universities across a broad range of disciplines, and demonstrate a capacity not only to conduct great research, but convert it into useful tools which create global impact.

[img source] The University of Canberra
The above story is based on materials provided by The Univerity of Canberra